Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

Nutt, John G., Gunzler, Steven A., Kirchhoff, Trish, Hogarth, Penelope, Weaver, Jerry L., Krams, Michael, Jamerson, Brenda, Menniti, Frank S. +1 more·2008·Movement Disorders
DOI 10.1002/mds.22169

Cited by (135)

Items 101–135 of 135

  1. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology
    Yong Wang, Gejuan Zhang, Yina Sun, Lu Yao, Huisheng Wang, Chengxue Du, Li Zhang, Jian Liu · 2018 · Behavioural Brain Research
  2. 1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators
    Christa C. Chrovian, Akinola Soyode-Johnson, Jessica L. Wall, Jason C. Rech, Jeffrey Schoellerman, Brian Lord, Kevin J. Coe, Nicholas I. Carruthers, Leslie Nguyen, Xiaohui Jiang et al. · 2019 · ACS Medicinal Chemistry Letters
  3. Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems
    Annalisa Pinna, Marcello Serra, Jacopo Marongiu, Micaela Morelli · 2020 · Parkinsonism & Related Disorders
  4. Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
    Melina Bordone, Ana Damianich, Alejandra Bernardi, Tomas Eidelman, Sara Sanz‐Blasco, Oscar S. Gershanik, María Elena Avale, Juan Esteban Ferrario · 2021 · eNeuro
  5. Expression and phosphorylation of glutamate receptor subunits and CaMKII in a mouse model of Parkinsonism
    Μαρία Κουτσοκέρα, Panagiotis Kafkalias, Panagiotis Giompres, Elias D. Kouvelas, Ada Mitsacos · 2014 · Brain Research
  6. Nondopaminergic Treatments for Parkinson’s Disease
    Philippe Huot, Susan Helen Fox · 2011 · Neurodegenerative Disease Management
  7. Molecular Mechanisms of l-DOPA-Induced Dyskinesia
    Maria Angela Cenci · 2016 · Handbook of behavioral neuroscience
  8. NMDARs Containing NR2B Subunit Do Not Contribute to the LTP Form of Hippocampal Plasticity: In Vivo Pharmacological Evidence in Rats
    Abdallah Ahnaou, Kobe Heleven, R. Biermans, Nikolay V. Manyakov, Wilhelmus H. I. M. Drinkenburg · 2021 · International Journal of Molecular Sciences
  9. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy
    Vincent A. Jourdain, Nicolas Morin, Laurent Grégoire, Marc Morissette, Thérèse Di Paolo · 2015 · Journal of neurosurgery
  10. Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors
    Patrick M. Callahan, Alvin V. Terry, Frederick R. Nelson, Robert A. Volkmann, Amrita Vinod, Mohd Zainuddin, Frank S. Menniti · 2020 · Neuropharmacology
  11. Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia
    Brik A. Kochoian, Cassandra Bure, Stella M. Papa · 2023 · Cells
  12. Roles of Ca2+/calmodulin-dependent protein kinase II in subcellular expression of striatal N-Methyl-D-aspartate receptors in L-3, 4-dihydroxyphenylalanine-induced dyskinetic rats
    Zhenguo Liu, Jing Gan, Qi Cheng · 2015 · Drug Design Development and Therapy
  13. NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
    Huei-Sheng Vincent Chen, Maryam Majdi · 2009 · Journal of Receptor Ligand and Channel Research
  14. Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An in-depth review
    Fatemeh Forouzanfar, Amir Mahmoud Ahmadzadeh, Ali Mohammad Pourbagher‐Shahri, Ali Gorji · 2025 · European Journal of Pharmacology
  15. Experimental Models of l-DOPA-Induced Dyskinesia
    Tom H. Johnston, Emma L. Lane · 2011 · International review of neurobiology
  16. Ion Channels as Drug Targets in Central Nervous System Disorders
    A.M. Waszkielewicz, A. Gunia, Natalia Szkaradek, Karolina Słoczyńska, S. Krupinska, Henryk Marona · 2013 · Current Medicinal Chemistry
  17. Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats
    Taiki Yabumoto, Brik A. Kochoian, Stefano Coletta, Oskar Laur, Xinping Huang, Cassandra Bure, Christopher B. Ware, Peng Jin, Stephen F. Traynelis, Stella M. Papa · 2025 · Neuropharmacology
  18. Glutamate Receptors and Levodopa-Induced Dyskinesia
    Barbara Picconi, Paolo Calabresi · 2014 · Springer eBooks
  19. Role of Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders
    Lotten K. N. Ragnarsson, Peter Ronald Dodd, Matthew R. Hynd · 2014 · Springer eBooks
  20. L-dopa dyskinesias
    Juan Ramirez‐Castaneda, Joseph J. Jankovic · 2015 · Cambridge University Press eBooks
  21. Molecular Mechanisms of l-DOPA-Induced Dyskinesia
    Maria Angela Cenci · 2010 · Handbook of behavioral neuroscience
  22. Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia
    Michael L. Martini, Sean N. Neifert, J Mocco, Fedor E. Panov, Winona Tse, Ruth Helen Walker, Jian Jun Jin, Fiona Gupta · 2019 · Journal of Movement Disorders
  23. MOLECULAR MECHANISMS UNDERLYING THE ACQUISITION, EXTINCTION AND REINSTATEMENT OF COCAINE-ASSOCIATED MEMORY: RELEVANCE TO ADDICTION PROCESSES By
    Shervin Liddie, Shervin Albert Liddie · 2016
  24. POLYAMINE MODULATION IN ALCOHOLISM: EXAMINATION USING A NOVEL SCREENING PROCEDURE DESIGNED TO PREDICT ANTI-RELAPSE AND NEUROPROTECTIVE EFFICACY
    Jetaime Lewis · 2011 · UKnowledge (University of Kentucky)
  25. Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease
    Sylvain Célanire, Benjamin Perry, Robert Lütjens, Sonia Maria Poli, Ian J. Reynolds · 2013 · Royal Society of Chemistry eBooks
  26. Impaired Dopamine–Glutamate Receptor Interactions in Some Neurological Disorders
    Miriam Ann Hickey, Carlos Cepeda · 2011 · Frontiers in neuroscience
  27. The NMDA receptor ligands in anti-depressant therapy
    Weronika Stasiuk, Joanna Warchulińska, Anna Olszewska, Ewa Poleszak · 2016 · Medycyna Ogólna i Nauki o Zdrowiu
  28. PET studies in Parkinson’s Disease Dyskinesias and Dementia
    Ahmed, Imtiaz · 2012 · Spiral (Imperial College London)
  29. Análise de preditores clínicos e genéticos para o surgimento de discinesias induzidas por L-DOPA na doença de Parkinson
    Bruno Lopes dos Santos · 2018
  30. Études de la subthalamotomie comme traitement des dyskinésies chez le primate parkinsonien
    Vincent A. Jourdain · 2013 · Corpus Université Laval (Université Laval)
  31. Ifenprodil Intracerebrally Offers Neuroprotection against 6-OHDA-Induced Toxicity in SD-Rats via Enhancing Autophagy Function
    Xinyu Zhao, Fugang Tian, Chunmin Guo, Xin Yu · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Glutamatergic Treatments for Parkinson’s Disease
    Fabrizio Gardoni · 2022 · Springer eBooks
  33. Modification d'expression de NR2B lors de dyskinésies de la patte avant chez le rat induites par traitement chronique à la L-DOPA ou par stimulation à haute fréquence du Noyau Subthalamique
    Adrien Quintana · 2011 · theses.fr (ABES)
  34. BindingDB Entry 50042770: Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
    BindingDB · 2013 · UC San Diego
  35. BindingDB Entry 50007475: 1
    BindingDB · 2021 · UC San Diego